The Development of Antibody-Drug Conjugates for Urothelial Carcinoma Treatment
10.22465/kjuo.2021.19.1.30
- Author:
Da Som CHOI
1
;
Su Jeong KANG
;
In Ho CHANG
;
Young Wook CHOI
Author Information
1. Department of Urology, Chung-Ang University College of Medicine, Seoul, Korea
- Publication Type:Review Article
- From:Korean Journal of Urological Oncology
2021;19(1):30-39
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Urothelial cancer is the seventh most common cancer among men worldwide. Bacille de Calmette-Guérin is a type of anticancer immunotherapy that has been used to treat targeted bladder cancer, but the number of patients with treatment-refractory advanced urothelial cancer, patients has been increasing recently. To overcome this, enfortumab vedotin (novel nectin-4 targeting antibody-drug conjugate) known as antibody-drug conjugate (ADC), was approved. We describe the clinical development process of ADC and the potential for future development as a bladder cancer treatment.
